|Articles|December 7, 2010

New TIDI Glove Products Added to Novation Contract

TIDI Products LLC, a manufacturer of single-use infection prevention products for medical and dental markets, has added three new gloves to its Novation LLC contract. The gloves include the 18 mil P2Â® HiRisk Latex Exam Gloves, 15 mil P2Â® SafetyPlus Latex Exam Gloves, and the 8 mil P2Â® Nitrile Exam Gloves.

The three gloves are use in high risk applications such as sterile processing/decontamination and chemotherapy drug compounding and administration. The 18 mil and 8 mil gloves are chemotherapy tested per the ASTM Standard D6978-05.

The existing contract, which began Nov. 1, 2010, runs through Oct. 31, 20111. The glove addition to the contract will complete Novations current offer to members for nitrile, vinyl and latex gloves.

Stay prepared and protected with the Infection Control Today newsletter, delivering essential updates, best practices, and expert insights for infection prevention professionals.

Related to this article

Weekly Rounds With Infection Control Today

October 30th, 2026

ICT Weekly Rounds: Ebola Execution Gaps, a Midge-Borne Virus Jumps to Humans, and IDWeek Findings

This week in infection prevention: Kenya’s Bundibugyo virus response shows why execution, not just planning, determines outcomes, and France reported the first known human Shamonda virus infection. Our roundup also covers brucellosis, blood donor screening, and long-acting HIV antibody findings from IDWeek 2026.

October 23rd, 2026

IDWeek 2026: ICU Study Finds Lower Glove Bioburden With PostCare Alcohol Application

An ICU study found that alcohol-based hand rub applied after patient care reduced glove bioburden, while staff raised feasibility concerns. Researchers stress that the practice does not replace glove changes or hand hygiene.

Image of Pathogens flying (Adobe Stock weerasak)

October 6th, 2026

How 3 Decades of SHEA Presidents Shaped the Science and Soul of Infection Prevention

Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.

IDweek 2026 Washington, DC (Adobe Stock)

October 29th, 2026

Jimmy Chang, PhD, Discusses Long-Acting HIV Antibody Therapy at IDWeek 2026

At IDWeek 2026, Jimmy Chang, PhD, discussed investigational HIV antibodies TMB-365 and TMB-380, explaining their complementary mechanisms, early study findings, and ongoing evaluation as a long-acting maintenance regimen.

At IDWeek 2026, Samuel Ntow discussed research finding reactive infection screening markers in 18.3% of replacement donor records from rural Ghana, highlighting opportunities for further evaluation and linkage to care.

October 28th, 2026

Ghana Blood Donor Screening Study: Infection Markers and Findings From IDWeek 2026

At IDWeek 2026, Samuel Ntow, MBChB, MPH, discussed research findings of reactive infection screening markers in 18.3% of replacement donor records from rural Ghana, highlighting opportunities for further evaluation and linkage to care.

Shamonda Virus Vector (midge) in a bottle (Image by author with AI)

October 27th, 2026

What Is Shamonda Virus? First Human Case in France and Implications for Infection Prevention

France’s first reported human Shamonda virus infection raises questions about transmission and vulnerable patients. Explore what investigators know, what remains uncertain, and why infection preventionists should follow this emerging story.

October 26th, 2026

IDWeek 2026: John Rex Discusses Antifungal Innovation and Career Connections

John Rex, MD, CMO of F2G, discusses investigational olorofim’s phase 3 findings, why new antifungals are difficult to develop, and how an oral option could help patients with limited treatment choices.

IDWeek, October 21 to 24 in Washington, DC (Adobe Stock)

October 26th, 2026

IDWeek 2026 Study Examines 875 Brucellosis Diagnoses in US Hospital Admissions

An analysis of 147 million US hospital admissions identified 875 adults with brucellosis diagnoses, highlighting demographic and regional differences while emphasizing exposure histories and uncertainty about underdiagnosis.